

Encorafenib plus binimetinib versus vemurafenib or encorafenib in BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

Lancet Oncology, The

19, 603-615

DOI: [10.1016/s1470-2045\(18\)30142-6](https://doi.org/10.1016/s1470-2045(18)30142-6)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Encorafenib " a new agent for advanced-stage disease. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 344-345.	12.5	7
2	Is there any interest in a new BRAF+MEK inhibitor combination in melanoma?. <i>Lancet Oncology</i> , The, 2018, 19, 580-581.	5.1	3
4	Cutaneous Side Effects of Targeted Therapy and Immunotherapy for Advanced Melanoma. <i>Scientifica</i> , 2018, 2018, 1-7.	0.6	14
5	Targeted Therapy for Colorectal Cancers With Non-V600 BRAF Mutations: Perspectives for Precision Oncology. <i>JCO Precision Oncology</i> , 2018, 2, 1-12.	1.5	10
9	The 150 most important questions in cancer research and clinical oncology series: questions 94+101. <i>Cancer Communications</i> , 2018, 38, 1-9.	3.7	9
10	Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 318.	3.5	66
12	Encorafenib/binimetinib for the treatment of BRAF-mutant advanced, unresectable, or metastatic melanoma: design, development, and potential place in therapy. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 9081-9089.	1.0	41
13	Spotlight in Plastic Surgery. <i>Plastic and Reconstructive Surgery</i> , 2018, 142, 1104-1106.	0.7	0
14	Frontiers in pigment cell and melanoma research. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 728-735.	1.5	10
15	Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 7095-7107.	1.0	187
16	Tumor Type-Agnostic Treatment and the Future of Cancer Therapy. <i>Targeted Oncology</i> , 2018, 13, 541-544.	1.7	7
17	Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1833-1844.	2.0	52
18	Targeted therapy: a potential oversight in trial protocol. <i>Lancet Oncology</i> , The, 2018, 19, e439.	5.1	1
19	Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLLUMBUS): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1315-1327.	5.1	469
20	Encorafenib plus binimetinib: an embarrassment of riches. <i>Lancet Oncology</i> , The, 2018, 19, 1263-1264.	5.1	7
21	Melanoma. <i>Lancet</i> , The, 2018, 392, 971-984.	6.3	1,016
22	MEK inhibitors for the treatment of NRAS mutant melanoma. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 2553-2565.	2.0	37
23	Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors. , 2018, 192, 65-73.		35

#	ARTICLE	IF	CITATIONS
24	Interleukin-1 Beta – A Friend or Foe in Malignancies?. International Journal of Molecular Sciences, 2018, 19, 2155.	1.8	268
25	Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs. Clinical and Experimental Metastasis, 2018, 35, 503-520.	1.7	9
26	Targeting oncogenic Raf protein-serine/threonine kinases in human cancers. Pharmacological Research, 2018, 135, 239-258.	3.1	154
27	Metastatic Melanoma: Recent Therapeutic Progress and Future Perspectives. Drugs, 2018, 78, 1197-1209.	4.9	34
28	Updates and challenges on treatment with BRAF/MEK-inhibitors in melanoma. Expert Opinion on Orphan Drugs, 2018, 6, 545-551.	0.5	6
29	The role of routine imaging in pediatric cutaneous melanoma. Pediatric Blood and Cancer, 2018, 65, e27412.	0.8	7
30	Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy. Pharmacological Research, 2018, 136, 151-159.	3.1	85
31	Encorafenib and Binimetinib: First Global Approvals. Drugs, 2018, 78, 1277-1284.	4.9	86
32	Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas. Clinical Cancer Research, 2018, 24, 6483-6494.	3.2	55
33	Immunological effects of BRAF+MEK inhibition. OncoImmunology, 2018, 7, e1468955.	2.1	66
34	Evolving Role of the Oncology Nurse in the Care of Patients with Melanoma. , 2019, , 791-817.		0
35	Melanoma Immunology and Immunotherapy. , 2019, , 651-665.		0
36	Cutaneous Adverse Events of Systemic Melanoma Treatments. , 2019, , 743-771.		0
37	Clinical outcomes of BRAF plus MEK inhibition in melanoma: A meta-analysis and systematic review. Cancer Medicine, 2019, 8, 5414-5424.	1.3	14
38	Cardiovascular Adverse Events Associated With BRAF and MEK Inhibitors. JAMA Network Open, 2019, 2, e198890.	2.8	96
40	Systemic Therapies for Advanced Melanoma. Dermatologic Clinics, 2019, 37, 409-423.	1.0	42
41	Neoadjuvant therapy of locally/regionally advanced melanoma. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591986695.	1.4	21
42	Src-Dependent DBL Family Members Drive Resistance to Vemurafenib in Human Melanoma. Cancer Research, 2019, 79, 5074-5087.	0.4	13

#	ARTICLE	IF	CITATIONS
43	Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management. <i>European Journal of Cancer</i> , 2019, 119, 97-106.	1.3	75
44	Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing. <i>BMC Cancer</i> , 2019, 19, 665.	1.1	42
45	A patent review of BRAF inhibitors: 2013-2018. <i>Expert Opinion on Therapeutic Patents</i> , 2019, 29, 595-603.	2.4	8
46	Stearoyl-CoA Desaturase 1 as a Therapeutic Target for the Treatment of Cancer. <i>Cancers</i> , 2019, 11, 948.	1.7	148
47	Metabolic flexibility in melanoma: A potential therapeutic target. <i>Seminars in Cancer Biology</i> , 2019, 59, 187-207.	4.3	62
48	Comprehensive Clinical Trial Data Summation for BRAF-MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma. <i>Oncologist</i> , 2019, 24, e1197-e1211.	1.9	15
49	Reprogramming lymphocytes for the treatment of melanoma: From biology to therapy. <i>Advanced Drug Delivery Reviews</i> , 2019, 141, 104-124.	6.6	14
50	Targeted therapy for malignant melanoma. <i>Current Opinion in Pharmacology</i> , 2019, 46, 116-121.	1.7	19
51	BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5369.	1.8	88
52	A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma. <i>European Journal of Cancer</i> , 2019, 123, 58-71.	1.3	45
53	Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with frontline BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab. <i>Cancer Medicine</i> , 2019, 8, 7637-7643.	1.3	44
54	The density and spatial tissue distribution of CD8+ and CD163+ immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors. , 2019, 7, 308.		51
56	Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma. <i>Cancers</i> , 2019, 11, 1642.	1.7	47
57	The Targeted Therapies Era Beyond the Surgical Point of View: What Spine Surgeons Should Know Before Approaching Spinal Metastases. <i>Cancer Control</i> , 2019, 26, 107327481987054.	0.7	16
58	Advances in the therapy of BRAF ^{V600E} metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 823-829.	1.1	5
59	Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents. <i>European Journal of Pharmacology</i> , 2019, 862, 172621.	1.7	65
60	Distinct Transcriptional Programming Drive Response to MAPK Inhibition in BRAF ^{V600} -Mutant Melanoma Patient-Derived Xenografts. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 2421-2432.	1.9	2
61	Encorafenib, Binimetinib, and Cetuximab in BRAF ^{V600E} -Mutated Colorectal Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 1632-1643.	13.9	918

#	ARTICLE	IF	CITATIONS
62	Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2019, 30, 1884-1901.	0.6	394
63	Targeted Therapy in Advanced Melanoma With Rare <i>BRAF</i> Mutations. <i>Journal of Clinical Oncology</i> , 2019, 37, 3142-3151.	0.8	83
64	Epigenetic Mechanisms of Escape from <i>BRAF</i> Oncogene Dependency. <i>Cancers</i> , 2019, 11, 1480.	1.7	31
65	<i>BRAF</i> exon 11 mutant melanoma and sensitivity to <i>BRAF</i> / <i>MEK</i> inhibition: Two case reports. <i>European Journal of Cancer</i> , 2019, 121, 109-112.	1.3	2
66	Choice of first-line therapy in metastatic melanoma. <i>Cancer</i> , 2019, 125, 666-669.	2.0	12
67	Targeted Therapy and Immunotherapy for Melanoma in Japan. <i>Current Treatment Options in Oncology</i> , 2019, 20, 7.	1.3	79
68	Cobimetinib in malignant melanoma: how to <i>MEK</i> an impact on long-term survival. <i>Future Oncology</i> , 2019, 15, 967-977.	1.1	10
69	Mechanisms of immunogenicity in colorectal cancer. <i>British Journal of Surgery</i> , 2019, 106, 1283-1297.	0.1	32
70	Tolerability of <i>BRAF</i> / <i>MEK</i> inhibitor combinations: adverse event evaluation and management. <i>ESMO Open</i> , 2019, 4, e000491.	2.0	140
71	Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma. <i>Frontiers in Immunology</i> , 2019, 10, 990.	2.2	86
72	Encorafenib inhibits migration, induces cell cycle arrest and apoptosis in colorectal cancer cells. <i>Molecular and Cellular Biochemistry</i> , 2019, 459, 113-120.	1.4	3
73	Frontline Therapy for <i>BRAF</i> -Mutated Metastatic Melanoma: How Do You Choose, and Is There One Correct Answer?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 564-571.	1.8	42
74	Endobronchial, laryngeal and mediastinal melanoma: a rare constellation of metastatic disease. <i>BMJ Case Reports</i> , 2019, 12, e228957.	0.2	1
75	Modelling bistable tumour population dynamics to design effective treatment strategies. <i>Journal of Theoretical Biology</i> , 2019, 474, 88-102.	0.8	19
76	Frequent Occurrence of <i>NRAS</i> and <i>BRAF</i> Mutations in Human Acral Naevi. <i>Cancers</i> , 2019, 11, 546.	1.7	8
77	Cutaneous Adverse Events of Systemic Melanoma Treatments. , 2019, , 1-29.		0
78	Targeting Molecular Pathways in Intracranial Metastatic Disease. <i>Frontiers in Oncology</i> , 2019, 9, 99.	1.3	10
79	Targeting the <i>MAPK</i> pathway in advanced <i>BRAF</i> wild-type melanoma. <i>Annals of Oncology</i> , 2019, 30, 503-505.	0.6	6

#	ARTICLE	IF	CITATIONS
80	Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591983082.	1.4	107
81	Encorafenib + binimetinib: a profile of their combined use in treating BRAF-mutated unresectable or metastatic melanoma. <i>Drugs and Therapy Perspectives</i> , 2019, 35, 151-159.	0.3	0
82	Systemic Therapy in BRAF V600E-Mutant Metastatic Colorectal Cancer: Recent Advances and Future Strategies. <i>Current Colorectal Cancer Reports</i> , 2019, 15, 53-60.	1.0	4
83	Properties of FDA-approved small molecule protein kinase inhibitors. <i>Pharmacological Research</i> , 2019, 144, 19-50.	3.1	377
84	Clinical Pharmacokinetic and Pharmacodynamic Considerations in the (Modern) Treatment of Melanoma. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1029-1043.	1.6	6
85	Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 381-392.	1.0	62
86	Targeting the ERK Signaling Pathway in Melanoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1483.	1.8	116
87	Targeting ERK1/2 protein-serine/threonine kinases in human cancers. <i>Pharmacological Research</i> , 2019, 142, 151-168.	3.1	202
88	Targeted agents or immuno-oncology therapies as first-line therapy for BRAF-mutated metastatic melanoma: a real-world study. <i>Future Oncology</i> , 2019, 15, 2933-2942.	1.1	32
89	Management of V600E and V600K BRAF-Mutant Melanoma. <i>Current Treatment Options in Oncology</i> , 2019, 20, 81.	1.3	28
90	Severe Drug-Induced Liver Injury from Combination Encorafenib/Binimetinib. <i>Case Reports in Oncological Medicine</i> , 2019, 2019, 1-4.	0.2	2
91	Clinical and Radiographic Response of Leptomeningeal and Brain Metastases to Encorafenib and Binimetinib in a Patient With BRAF V600E-Mutated Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2019, 14, e269-e271.	0.5	4
92	Adjuvant systemic therapy in high-risk melanoma. <i>Melanoma Research</i> , 2019, 29, 358-364.	0.6	16
93	Encorafenib and binimetinib for the treatment of BRAF-mutated metastatic melanoma in the setting of combined hepatic and renal impairment. <i>BMJ Case Reports</i> , 2019, 12, e230974.	0.2	1
94	Evolving management of positive regional lymph nodes in melanoma: Past, present and future directions. <i>Oncology Reviews</i> , 2019, 13, 433.	0.8	9
95	An update on adjuvant systemic therapies in melanoma. <i>Melanoma Management</i> , 2019, 6, MMT28.	0.1	10
96	Real-world treatment patterns and clinical outcomes among patients with advanced melanoma. <i>Medicine (United States)</i> , 2019, 98, e16328.	0.4	30
97	Overcoming the resistance to BRAF inhibitor by the double BRAF and MEK inhibitions in advanced melanoma: a case report. <i>Anti-Cancer Drugs</i> , 2019, 30, 1052-1054.	0.7	3

#	ARTICLE	IF	CITATIONS
98	Optimizing Biologic Sequencing in Metastatic Colorectal Cancer: First Line and Beyond. <i>Current Oncology</i> , 2019, 26, 33-42.	0.9	7
99	Efficacy and Adverse Events in Metastatic Melanoma Patients Treated with Combination BRAF Plus MEK Inhibitors Versus BRAF Inhibitors: A Systematic Review. <i>Cancers</i> , 2019, 11, 1950.	1.7	24
100	Wide field retinal imaging and the detection of drug associated retinal toxicity. <i>International Journal of Retina and Vitreous</i> , 2019, 5, 26.	0.9	18
101	Effects of pharmacogenetic variants on vemurafenib-related toxicities in patients with melanoma. <i>Pharmacogenomics</i> , 2019, 20, 1283-1290.	0.6	2
102	BRAF ⁱ /MEK ⁱ in patients with metastatic melanoma: predictive factors of complete response. <i>Future Oncology</i> , 2019, 15, 133-139.	1.1	1
103	A multidimensional impedance platform for the real-time analysis of single and combination drug pharmacology in patient-derived viable melanoma models. <i>Biosensors and Bioelectronics</i> , 2019, 123, 185-194.	5.3	15
104	An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system. <i>European Journal of Cancer</i> , 2019, 107, 175-185.	1.3	13
105	Clinical and economic outcomes associated with treatment sequences in patients with BRAF ⁱ -mutant advanced melanoma. <i>Immunotherapy</i> , 2019, 11, 283-295.	1.0	24
106	Dermatology today and tomorrow: from symptom control to targeted therapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 3-36.	1.3	31
107	Advanced stage melanoma therapies: Detailing the present and exploring the future. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 133, 99-111.	2.0	48
108	The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in BRAF ⁱ -mutated advanced melanoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 686-692.	1.3	17
109	Brain Distribution and Active Efflux of Three panRAF Inhibitors: Considerations in the Treatment of Melanoma Brain Metastases. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 368, 446-461.	1.3	15
110	Efficacy of rechallenge with BRAF inhibition therapy in patients with advanced BRAFV600 mutant melanoma. <i>Clinical and Translational Oncology</i> , 2019, 21, 1061-1066.	1.2	11
111	Comparative and combined effectiveness of innovative therapies in cancer: a literature review. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 205-216.	0.6	3
112	Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 259-266.	1.3	44
113	Monitoring Melanoma Using Circulating Free DNA. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 1-12.	3.3	26
114	Management of local or regional non-nodal disease. <i>Journal of Surgical Oncology</i> , 2019, 119, 187-199.	0.8	8
116	Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy. <i>Cancer</i> , 2019, 125, 884-891.	2.0	43

#	ARTICLE	IF	CITATIONS
117	Targeting metabolic reprogramming in metastatic melanoma: The key role of nicotinamide phosphoribosyltransferase (NAMPT). <i>Seminars in Cell and Developmental Biology</i> , 2020, 98, 192-201.	2.3	30
118	Network indirect comparison of 3 BRAF+MEK inhibitors for the treatment of advanced BRAF mutated melanoma. <i>Clinical and Translational Oncology</i> , 2020, 22, 900-907.	1.2	8
119	Novel functional proteins coded by the human genome discovered in metastases of melanoma patients. <i>Cell Biology and Toxicology</i> , 2020, 36, 261-272.	2.4	9
120	Current Clinical Trials in the Treatment of Advanced Melanomas. <i>Surgical Clinics of North America</i> , 2020, 100, 201-208.	0.5	3
121	Neoadjuvant BRAF-targeted therapy in regionally advanced and oligometastatic melanoma. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 86-95.	1.5	11
122	Age-Specific Incidence of Melanoma in the United States. <i>JAMA Dermatology</i> , 2020, 156, 57.	2.0	123
124	Principles of Targeted Therapy for Melanoma. <i>Surgical Clinics of North America</i> , 2020, 100, 175-188.	0.5	40
125	Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series. <i>Cancer</i> , 2020, 126, 523-530.	2.0	43
126	Epigenetic <i>EGFR</i> Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas. <i>Clinical Cancer Research</i> , 2020, 26, 902-909.	3.2	29
127	A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 460-467.	1.9	60
128	Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response: A retrospective single-centre experience in patients with BRAF-mutated melanoma. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 498-506.	1.5	11
129	The mutational landscape of mucosal melanoma. <i>Seminars in Cancer Biology</i> , 2020, 61, 139-148.	4.3	112
130	Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. <i>European Journal of Cancer</i> , 2020, 126, 33-44.	1.3	130
131	The challenge of identifying which stage III melanoma patients need adjuvant treatment and with what. <i>Annals of Oncology</i> , 2020, 31, 11-12.	0.6	2
132	Considering adjuvant therapy for stage II melanoma. <i>Cancer</i> , 2020, 126, 1166-1174.	2.0	32
133	European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2019. <i>European Journal of Cancer</i> , 2020, 126, 159-177.	1.3	154
134	Precision Medicine in the Treatment of Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 1-13.	0.6	7
135	Identifying the optimum first-line therapy in BRAF-mutant metastatic melanoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 53-62.	1.1	6

#	ARTICLE	IF	CITATIONS
136	Metabolic imaging using hyperpolarized ¹³ C-pyruvate to assess sensitivity to the BRAF inhibitor vemurafenib in melanoma cells and xenografts. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 1934-1944.	1.6	13
137	An evaluation of encorafenib for the treatment of melanoma. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 155-161.	0.9	11
139	Targeting BRAF and MEK inhibitors in melanoma in the metastatic, neoadjuvant and adjuvant setting. <i>Current Opinion in Oncology</i> , 2020, 32, 85-90.	1.1	8
140	Overcoming Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutated Tumours. <i>Journal of Oncology</i> , 2020, 2020, 1-14.	0.6	14
141	Using methylation profiling to diagnose systemic metastases of pleomorphic xanthoastrocytoma. <i>Neuro-Oncology Advances</i> , 2020, 2, vdz057.	0.4	2
142	Discoïdin Domain Receptors in Melanoma: Potential Therapeutic Targets to Overcome MAPK Inhibitor Resistance. <i>Frontiers in Oncology</i> , 2020, 10, 1748.	1.3	9
143	Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review. <i>Cancers</i> , 2020, 12, 2801.	1.7	73
144	Real-world treatment practice in patients with advanced melanoma. <i>Wspolczesna Onkologia</i> , 2020, 24, 118-124.	0.7	6
145	BRAF-Mutant Metastatic Melanoma Presenting as a Fungating Soft Tissue Mass Suspicious for Sarcoma. <i>Operative Techniques in Orthopaedics</i> , 2020, 30, 100804.	0.2	0
146	Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma. <i>Uppsala Journal of Medical Sciences</i> , 2020, 125, 325-329.	0.4	8
147	Malignant melanoma metastasis in the gallbladder. A case report of an unusual metastatic site. <i>International Journal of Surgery Case Reports</i> , 2020, 75, 372-375.	0.2	7
148	Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy. <i>Cancers</i> , 2020, 12, 2870.	1.7	64
150	KRAS: From undruggable to a druggable Cancer Target. <i>Cancer Treatment Reviews</i> , 2020, 89, 102070.	3.4	136
151	A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with BRAFV600E/K-mutant Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 5102-5112.	3.2	23
152	Targeted and immunotherapies in BRAF mutant melanoma: where we stand and what to expect. <i>British Journal of Dermatology</i> , 2021, 185, 253-262.	1.4	20
153	Cancer Stem Cells and the Slow Cycling Phenotype: How to Cut the Gordian Knot Driving Resistance to Therapy in Melanoma. <i>Cancers</i> , 2020, 12, 3368.	1.7	15
154	A Blue Light-Inducible CRISPR-Cas9 System for Inhibiting Progression of Melanoma Cells. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 606593.	1.6	13
155	BRAF: A Two-Faced Janus. <i>Cells</i> , 2020, 9, 2549.	1.8	23

#	ARTICLE	IF	CITATIONS
156	Melanoma Persister Cells Are Tolerant to BRAF/MEK Inhibitors via ACOX1-Mediated Fatty Acid Oxidation. <i>Cell Reports</i> , 2020, 33, 108421.	2.9	77
157	The Role of BRAF in Metastatic Colorectal Carcinoma—Past, Present, and Future. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9001.	1.8	8
158	Toxicity of combined targeted therapy and concurrent radiotherapy in metastatic melanoma patients: a single-center retrospective analysis. <i>Melanoma Research</i> , 2020, 30, 552-561.	0.6	5
159	Overcoming Immune Evasion in Melanoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8984.	1.8	88
160	RAGE Signaling in Melanoma Tumors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8989.	1.8	13
161	PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma. <i>Nature Communications</i> , 2020, 11, 6262.	5.8	50
162	Hydroxynaphthalenecarboxamides and substituted piperazinypropandiols, two new series of BRAF inhibitors. A theoretical and experimental study. <i>Bioorganic Chemistry</i> , 2020, 103, 104145.	2.0	8
163	Toxic epidermal necrolysis in a melanoma patient under targeted therapy with encorafenib and binimetinib. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 1159-1161.	0.4	0
164	Current State of Target Treatment in BRAF Mutated Melanoma. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 154.	1.6	82
165	Adjuvant Therapy for Melanoma: Past, Current, and Future Developments. <i>Cancers</i> , 2020, 12, 1994.	1.7	26
166	Response to Ipilimumab/Nivolumab Rechallenge and BRAF Inhibitor/MEK Inhibitor Rechallenge in a Patient with Advanced Metastatic Melanoma Previously Treated with BRAF Targeted Therapy and Immunotherapy. <i>Case Reports in Oncological Medicine</i> , 2020, 2020, 1-6.	0.2	3
167	A Comprehensive Review of Clinical Cardiotoxicity Incidence of FDA-Approved Small-Molecule Kinase Inhibitors. <i>Frontiers in Pharmacology</i> , 2020, 11, 891.	1.6	48
168	Preclinical discovery and clinical development of encorafenib for the treatment of melanoma. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 1373-1380.	2.5	7
169	Genetic Biomarkers in Melanoma of the Ocular Region: What the Medical Oncologist Should Know. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5231.	1.8	15
170	Clinical Development of BRAF plus MEK Inhibitor Combinations. <i>Trends in Cancer</i> , 2020, 6, 797-810.	3.8	169
171	The MAP kinase signal transduction pathway: promising therapeutic targets used in the treatment of melanoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 687-701.	1.1	6
174	Safety and efficacy evaluation of encorafenib plus binimetinib for the treatment of advanced BRAF-mutant melanoma patients. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1229-1236.	1.0	3
175	Reverse transcriptase inhibition potentiates target therapy in BRAF-mutant melanomas: effects on cell proliferation, apoptosis, DNA-damage, ROS induction and mitochondrial membrane depolarization. <i>Cell Communication and Signaling</i> , 2020, 18, 150.	2.7	4

#	ARTICLE	IF	CITATIONS
176	Cellular Mechanisms Accounting for the Refractoriness of Colorectal Carcinoma to Pharmacological Treatment. <i>Cancers</i> , 2020, 12, 2605.	1.7	21
177	BRAF and MEK inhibitors rechallenge as effective treatment for patients with metastatic melanoma. <i>Melanoma Research</i> , 2020, 30, 465-471.	0.6	14
178	B-Raf-Mutated Melanoma. , 2020, , .		0
179	Clinical Implications of Acquired BRAF Inhibitors Resistance in Melanoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9730.	1.8	15
180	Comparative Risks of High-Grade Adverse Events Among FDA-Approved Systemic Therapies in Advanced Melanoma: Systematic Review and Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 571135.	1.3	2
181	Small moleculesâ€™ Giant leaps for immuno-oncology. <i>Progress in Medicinal Chemistry</i> , 2020, 59, 1-62.	4.1	2
182	Current Molecular Markers of Melanoma and Treatment Targets. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3535.	1.8	45
183	Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic Therapy. <i>Cancers</i> , 2020, 12, 1176.	1.7	11
184	BRAF mutation and its inhibitors in sarcoma treatment. <i>Cancer Medicine</i> , 2020, 9, 4881-4896.	1.3	26
185	MEK Inhibition Suppresses Growth of Atypical Teratoid/Rhabdoid Tumors. <i>Journal of Neuropathology and Experimental Neurology</i> , 2020, 79, 746-753.	0.9	4
186	Metastatic melanoma: therapeutic agents in preclinical and early clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 739-753.	1.9	2
187	Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , 2020, 395, 1558-1568.	6.3	188
188	A combinatorial strategy for overcoming primary and acquired resistance of MEK inhibition in colorectal cancer. <i>Experimental Cell Research</i> , 2020, 393, 112060.	1.2	5
189	The Landmark Series: Neoadjuvant Systemic Therapy (NAST) for Stage 3 Melanoma Patients â€™ A Potential Paradigm Shift in Management. <i>Annals of Surgical Oncology</i> , 2020, 27, 2188-2200.	0.7	4
190	Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. <i>Translational Oncology</i> , 2020, 13, 100795.	1.7	26
191	Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in Oncology. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e292-e308.	1.8	3
192	Acute Kidney Injury Following Encorafenib and Binimetinib for Metastatic Melanoma. <i>Kidney Medicine</i> , 2020, 2, 373-375.	1.0	5
193	The MNK1/2-eIF4E Axis as a Potential Therapeutic Target in Melanoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4055.	1.8	23

#	ARTICLE	IF	CITATIONS
194	Targeted Therapy for Non-Small Cell Lung Cancer. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 409-434.	0.8	11
195	Targeted Therapy and Traditional Chemotherapy in Melanoma and Cutaneous Squamous Cell Carcinoma. <i>Facial Plastic Surgery</i> , 2020, 36, 186-193.	0.5	5
196	In Vitro Biophysical and Biological Characterization of Lipid Nanoparticles Co-Encapsulating Oncosuppressors miR-199b-5p and miR-204-5p as Potentiators of Target Therapy in Metastatic Melanoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1930.	1.8	15
197	Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. <i>European Journal of Cancer</i> , 2020, 130, 126-138.	1.3	84
198	Cutaneous Adverse Events of Anti-PD-1 Therapy and BRAF Inhibitors. <i>Current Treatment Options in Oncology</i> , 2020, 21, 29.	1.3	11
199	Targeting complex, adaptive responses in melanoma therapy. <i>Cancer Treatment Reviews</i> , 2020, 86, 101997.	3.4	8
200	The use of circulating cell-free tumor DNA in routine diagnostics of metastatic melanoma patients. <i>Scientific Reports</i> , 2020, 10, 4940.	1.6	12
201	The discovery and development of binimetinib for the treatment of melanoma. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 745-754.	2.5	25
202	Long-Term Outcomes in BRAF-Mutated Melanoma Treated with Combined Targeted Therapy or Immune Checkpoint Blockade: Are We Approaching a True Cure?. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 493-504.	3.3	30
203	MicroRNAs as Key Players in Melanoma Cell Resistance to MAPK and Immune Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4544.	1.8	24
204	New Treatment Options for Advanced Biliary Tract Cancer. <i>Current Treatment Options in Oncology</i> , 2020, 21, 63.	1.3	27
205	Response and survival of metastatic melanoma patients treated with immune checkpoint inhibition for recurrent disease on adjuvant dendritic cell vaccination. <i>OncolImmunology</i> , 2020, 9, 1738814.	2.1	13
206	BRAF inhibition in melanoma is associated with the dysregulation of histone methylation and histone methyltransferases. <i>Neoplasia</i> , 2020, 22, 376-389.	2.3	14
207	Adjuvant Therapy for Cutaneous Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 455-465.	0.6	1
208	Review of the Agnostic-Type Treatment Approach: Treating Cancer by Mutations, Not by Location. <i>Oncology and Therapy</i> , 2020, 8, 59-66.	1.0	4
209	Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study. <i>Cancers</i> , 2020, 12, 1666.	1.7	17
210	BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions. <i>Cancers</i> , 2020, 12, 1823.	1.7	82
211	Impact of the Protein Data Bank on antineoplastic approvals. <i>Drug Discovery Today</i> , 2020, 25, 837-850.	3.2	24

#	ARTICLE	IF	CITATIONS
212	An overview of binimetinib for the treatment of melanoma. Expert Opinion on Pharmacotherapy, 2020, 21, 747-754.	0.9	8
213	Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials. BMC Cancer, 2020, 20, 157.	1.1	3
214	Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutant Melanoma. Clinical Cancer Research, 2020, 26, 46-53.	3.2	32
215	Encorafenib, binimetinib and cetuximab combined therapy for patients with <i>BRAF</i> V600E mutant metastatic colorectal cancer. Future Oncology, 2020, 16, 161-173.	1.1	9
216	Left ventricular ejection fraction decrease related to BRAF and/or MEK inhibitors in metastatic melanoma patients: A retrospective analysis. Cancer Medicine, 2020, 9, 2611-2620.	1.3	16
217	Conjunctival Melanoma: Current Treatments and Future Options. American Journal of Clinical Dermatology, 2020, 21, 371-381.	3.3	33
218	Hyperkeratotic Skin Adverse Events Induced by Anticancer Treatments: A Comprehensive Review. Drug Safety, 2020, 43, 395-408.	1.4	15
219	The potential of BRAF-targeted therapy combined with immunotherapy in melanoma. Expert Review of Anticancer Therapy, 2020, 20, 131-136.	1.1	9
220	Co-targeting bromodomain and extraterminal proteins and MCL1 induces synergistic cell death in melanoma. International Journal of Cancer, 2020, 147, 2176-2189.	2.3	16
222	The Role of Anti-Angiogenics in Pre-Treated Metastatic BRAF-Mutant Colorectal Cancer: A Pooled Analysis. Cancers, 2020, 12, 1022.	1.7	16
223	Synthetic Approaches to New Drugs Approved during 2018. Journal of Medicinal Chemistry, 2020, 63, 10652-10704.	2.9	33
224	Changing Therapeutic Landscape for Melanoma With Multiple Brain Metastases. Neurosurgery, 2020, 87, 498-515.	0.6	3
225	Toward a More Precise Future for Oncology. Cancer Cell, 2020, 37, 431-442.	7.7	21
226	Improvements in Clinical Outcomes for <i>BRAF</i> V600E-Mutant Metastatic Colorectal Cancer. Clinical Cancer Research, 2020, 26, 4435-4441.	3.2	17
227	Systemic Therapy for Melanoma: ASCO Guideline. Journal of Clinical Oncology, 2020, 38, 3947-3970.	0.8	190
228	Encorafenib with Binimetinib for the Treatment of Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics - Open, 2021, 5, 13-22.	0.9	5
229	Treatment of Advanced Melanoma in 2020 and Beyond. Journal of Investigative Dermatology, 2021, 141, 23-31.	0.3	193
230	Emerging strategies to treat rare and intractable subtypes of melanoma. Pigment Cell and Melanoma Research, 2021, 34, 44-58.	1.5	22

#	ARTICLE	IF	CITATIONS
231	Successful Switch to Vemurafenib Plus Cobimetinib After Dabrafenib Plus Trametinib Toxicity in BRAFV600E-Mutant Metastatic Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021, 22, e54-e56.	1.1	3
233	Management of melanoma brain metastases: Evidence-based clinical practice guidelines by Cancer Council Australia. <i>European Journal of Cancer</i> , 2021, 142, 10-17.	1.3	16
234	Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors. <i>Targeted Oncology</i> , 2021, 16, 37-46.	1.7	5
235	AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 238-249.	1.9	13
236	State of Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 1-27.	0.9	4
237	Design, synthesis, and biological evaluation of novel imidazole derivatives possessing terminal sulphonamides as potential BRAFV600E inhibitors. <i>Bioorganic Chemistry</i> , 2021, 106, 104508.	2.0	20
238	LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 2061-2073.	3.2	39
239	Mechanisms of Resistance to BRAF-Targeted Melanoma Therapies. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 1-10.	3.3	12
240	Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial. <i>Targeted Oncology</i> , 2021, 16, 47-57.	1.7	8
242	Advances in anti-BRAF therapies for lung cancer. <i>Investigational New Drugs</i> , 2021, 39, 879-890.	1.2	22
243	Melanoom en andere huidtumoren. , 2021, , 515-526.		0
244	Skin Cancer: Molecular Biomarker for Diagnosis, Prognosis, Prevention, and Targeted Therapy. , 2021, , 101-130.		0
245	Drug resistance in targeted cancer therapies with RAF inhibitors. , 2021, 4, 665-683.		9
246	BRAF/MEK inhibitors for BRAF V600E-mutant cancers in non-approved setting: a case series. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 437-441.	1.1	5
247	Clinical Practice Guideline on Melanoma From the Spanish Academy of Dermatology and Venereology (AEDV). <i>Actas Dermo-sifiligráficas</i> , 2021, 112, 142-152.	0.2	2
248	Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling. <i>Cancer Discovery</i> , 2021, 11, 1716-1735.	7.7	30
249	Malignant Melanoma of the Gastrointestinal Tract: Symptoms, Diagnosis, and Current Treatment Options. <i>Cells</i> , 2021, 10, 327.	1.8	37
250	Adaptive Therapy for Metastatic Melanoma: Predictions from Patient Calibrated Mathematical Models. <i>Cancers</i> , 2021, 13, 823.	1.7	44

#	ARTICLE	IF	CITATIONS
252	Comparison of Solid Tumor Treatment Response Observed in Clinical Practice With Response Reported in Clinical Trials. <i>JAMA Network Open</i> , 2021, 4, e2036741.	2.8	12
253	Defining and Targeting BRAF Mutations in Solid Tumors. <i>Current Treatment Options in Oncology</i> , 2021, 22, 30.	1.3	25
254	Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). <i>Nature Medicine</i> , 2021, 27, 301-309.	15.2	218
255	The association between immune checkpoint or BRAF/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma. <i>European Journal of Cancer</i> , 2021, 144, 215-223.	1.3	9
256	Efficacy of BRAF Inhibitors in Combination With Stereotactic Radiosurgery for the Treatment of Melanoma Brain Metastases: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 586029.	1.3	4
257	Melanoma of unknown primary: New perspectives for an old story. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 158, 103208.	2.0	37
258	Relatively mild symptoms after chronic overdose with a double-dose encorafenib: a case report. <i>Anti-Cancer Drugs</i> , 2021, 32, 589-591.	0.7	1
259	Outcome of combination therapy using BRAF and MEK inhibitors among Asian patients with advanced melanoma: An analysis of 112 cases. <i>European Journal of Cancer</i> , 2021, 145, 210-220.	1.3	27
260	Melanoma cutáneo. <i>Medicine</i> , 2021, 13, 1493-1505.	0.0	1
261	Multiplexed Immunohistochemistry and Digital Pathology as the Foundation for Next-Generation Pathology in Melanoma: Methodological Comparison and Future Clinical Applications. <i>Frontiers in Oncology</i> , 2021, 11, 636681.	1.3	22
262	Translating Molecular Profiling of Soft Tissue Sarcomas into Daily Clinical Practice. <i>Diagnostics</i> , 2021, 11, 512.	1.3	3
263	BRAF inhibitor treatment is feasible in the oldest-old advanced melanoma patients. <i>Melanoma Research</i> , 2021, 31, 218-223.	0.6	4
264	Efficacy of Targeted Radionuclide Therapy Using [¹³¹ I]ICF01012 in 3D Pigmented BRAF- and NRAS-Mutant Melanoma Models and In Vivo NRAS-Mutant Melanoma. <i>Cancers</i> , 2021, 13, 1421.	1.7	5
265	Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a 5-Fluoro-4-(3 <i>H</i>)-quinazolinone Aryl Urea pan-RAF Kinase Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 3940-3955.	2.9	17
266	BRAF Gene and Melanoma: Back to the Future. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3474.	1.8	40
267	SEOM clinical guideline for the management of cutaneous melanoma (2020). <i>Clinical and Translational Oncology</i> , 2021, 23, 948-960.	1.2	22
268	Systemic Therapy of Metastatic Melanoma: On the Road to Cure. <i>Cancers</i> , 2021, 13, 1430.	1.7	50
269	Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3123-3135.	2.0	6

#	ARTICLE	IF	CITATIONS
270	Blood-Based Detection of BRAF V600E in Gliomas and Brain Tumor Metastasis. <i>Cancers</i> , 2021, 13, 1227.	1.7	9
271	Emerging PD-1/PD-L1 antagonists for the treatment of malignant melanoma. <i>Expert Opinion on Emerging Drugs</i> , 2021, 26, 79-92.	1.0	13
272	<i>BRAF</i> V600E/V600K Mutations versus Nonstandard Alterations: Prognostic Implications and Therapeutic Outcomes. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1072-1079.	1.9	6
273	Drugs Associated With the Development of Palmoplantar Keratoderma: A Systematic Review. <i>Journal of Cutaneous Medicine and Surgery</i> , 2021, 25, 553-554.	0.6	3
274	Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 301-314.	3.3	18
275	Neoadjuvant Cytoreductive Treatment With BRAF/MEK Inhibition of Prior Unresectable Regionally Advanced Melanoma to Allow Complete Surgical Resection, REDUCTOR. <i>Annals of Surgery</i> , 2021, 274, 383-389.	2.1	28
276	Development and validation of a web-based patient decision aid for immunotherapy for patients with metastatic melanoma: study protocol for a multicenter randomized trial. <i>Trials</i> , 2021, 22, 294.	0.7	1
277	The Role of Systemic Therapy in Advanced Cutaneous Melanoma of the Head and Neck. <i>Otolaryngologic Clinics of North America</i> , 2021, 54, 329-342.	0.5	1
278	A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma. <i>ESMO Open</i> , 2021, 6, 100050.	2.0	14
279	High sensitivity sanger sequencing detection of BRAF mutations in metastatic melanoma FFPE tissue specimens. <i>Scientific Reports</i> , 2021, 11, 9043.	1.6	13
280	Development of Immunotherapy Combination Strategies in Cancer. <i>Cancer Discovery</i> , 2021, 11, 1368-1397.	7.7	130
282	Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial. <i>PLoS ONE</i> , 2021, 16, e0248097.	1.1	5
283	ERK1/2: An Integrator of Signals That Alters Cardiac Homeostasis and Growth. <i>Biology</i> , 2021, 10, 346.	1.3	17
284	Safety and Tolerability of BRAF Inhibitor and BRAF Inhibitor-Based Combination Therapy in Chinese Patients With Advanced Melanoma: A Real World Study. <i>Frontiers in Oncology</i> , 2021, 11, 582676.	1.3	1
285	Case Report: Rechallenge With BRAF and MEK Inhibitors in Metastatic Melanoma: A Further Therapeutic Option in Salvage Setting?. <i>Frontiers in Oncology</i> , 2021, 11, 645008.	1.3	6
286	Sprouty4 negatively regulates ERK/MAPK signaling and the transition from in situ to invasive breast ductal carcinoma. <i>PLoS ONE</i> , 2021, 16, e0252314.	1.1	3
287	Surgery of small bowel melanoma metastases in the era of efficient medical therapies. <i>Melanoma Research</i> , 2021, Publish Ahead of Print, 358-365.	0.6	2
289	Impact of Circulating and Tissue Biomarkers in Adjuvant and Neoadjuvant Therapy for High-Risk Melanoma: Ready for Prime Time?. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 511-522.	3.3	6

#	ARTICLE	IF	CITATIONS
290	RAF mutations confer resistance to the RAF inhibitor vemurafenib in melanoma. <i>Nature</i> , 2011, 473, 418-423.	13.7	64
291	Dramatic response to encorafenib in a patient with metastatic melanoma harboring the BRAF V600E mutation. <i>American Journal of Hematology</i> , 2021, 96, E295-E298.	2.0	1
292	The Role of Senescent Cells in Acquired Drug Resistance and Secondary Cancer in BRAFi-Treated Melanoma. <i>Cancers</i> , 2021, 13, 2241.	1.7	8
293	A Case of Bilateral Multifocal Choroiditis Associated with BRAF/MEK Inhibitor Use for Metastatic Cutaneous Melanoma. <i>Ocular Immunology and Inflammation</i> , 2021, , 1-5.	1.0	6
294	Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma—A Retrospective Multicenter ADOReg Study. <i>Cancers</i> , 2021, 13, 2312.	1.7	11
295	Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries. <i>Cancer Medicine</i> , 2021, 10, 3862-3872.	1.3	17
296	Heart Failure With Targeted Cancer Therapies. <i>Circulation Research</i> , 2021, 128, 1576-1593.	2.0	33
297	Decreased survival in patients treated by chemotherapy after targeted therapy compared to immunotherapy in metastatic melanoma. <i>Cancer Medicine</i> , 2021, 10, 3155-3164.	1.3	5
298	A Validated LC-MS/MS Assay for the Simultaneous Quantification of the FDA-Approved Anticancer Mixture (Encorafenib and Binimetinib): Metabolic Stability Estimation. <i>Molecules</i> , 2021, 26, 2717.	1.7	7
299	Systemic Therapy for Head and Neck Skin Cancers. <i>Face</i> , 2021, 2, 121-130.	0.1	0
300	Clinical Manifestations and Treatment Outcomes of Metastatic Melanoma With Bone Marrow Infiltration. <i>American Journal of Therapeutics</i> , 2021, Publish Ahead of Print, .	0.5	1
301	Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition. <i>European Journal of Cancer</i> , 2021, 148, 61-75.	1.3	15
302	Metabolic Interplay between the Immune System and Melanoma Cells: Therapeutic Implications. <i>Biomedicines</i> , 2021, 9, 607.	1.4	12
303	CDK4/6 Inhibitors in Melanoma: A Comprehensive Review. <i>Cells</i> , 2021, 10, 1334.	1.8	31
304	Recent Advances in the Treatment of Melanoma. <i>New England Journal of Medicine</i> , 2021, 384, 2229-2240.	13.9	201
305	Rethinking therapeutic development for CNS metastatic disease. <i>Experimental Dermatology</i> , 2021, , .	1.4	1
306	Cutaneous melanoma in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28992.	0.8	9
307	Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 518.	1.1	8

#	ARTICLE	IF	CITATIONS
308	Chronic Unilateral Uveitis with Macular Edema Secondary to Dabrafenib for Pilocytic Astrocytoma. Case Reports in Ophthalmology, 2021, 12, 574-577.	0.3	3
309	First line immunotherapy extends brain metastasis free survival, improves overall survival, and reduces the incidence of brain metastasis in patients with advanced melanoma. Cancer Reports, 2021, 4, e1419.	0.6	4
310	Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy. Frontiers in Oncology, 2021, 11, 670726.	1.3	26
311	Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial. Lung Cancer, 2021, 156, 91-99.	0.9	11
312	Melanoma genomics: a state-of-the-art review of practical clinical applications*. British Journal of Dermatology, 2021, 185, 272-281.	1.4	12
313	Novel adjuvant options for cutaneous melanoma. Annals of Oncology, 2021, 32, 854-865.	0.6	31
314	Systematic review of combinations of targeted or immunotherapy in advanced solid tumors. , 2021, 9, e002459.		41
315	Advances in the discovery and development of melanoma drug therapies. Expert Opinion on Drug Discovery, 2021, 16, 1319-1347.	2.5	9
316	Unraveling the Wide Spectrum of Melanoma Biomarkers. Diagnostics, 2021, 11, 1341.	1.3	55
317	New systemic therapies for cutaneous melanoma: why, who and what. Italian Journal of Dermatology and Venereology, 2021, 156, 344-355.	0.1	2
318	Treatment of Advanced Metastatic Melanoma. Dermatology Practical and Conceptual, 2021, 11, 2021164S.	0.5	10
319	Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS). European Journal of Cancer, 2021, 152, 116-128.	1.3	7
320	Quadruple editing of the MAPK and PI3K pathways effectively blocks the progression of KRAS-mutated colorectal cancer cells. Cancer Science, 2021, 112, 3895-3910.	1.7	3
321	Prognostic Roles of BRAF, KIT, NRAS, IGF2R and SF3B1 Mutations in Mucosal Melanomas. Cells, 2021, 10, 2216.	1.8	8
322	Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: a comprehensive review. ESMO Open, 2021, 6, 100223.	2.0	18
323	Current treatment strategy for resectable scalp and neck melanoma. Opuholi Golovy I Sei, 2021, 11, 50-56.	0.1	1
324	An update of new small-molecule anticancer drugs approved from 2015 to 2020. European Journal of Medicinal Chemistry, 2021, 220, 113473.	2.6	27
325	Anuric Kidney Failure in a Patient With Metastatic Melanoma. JAMA Oncology, 2021, 7, 1567.	3.4	1

#	ARTICLE	IF	CITATIONS
326	Treatment beyond progression and locoregional approaches in selected patients with BRAF-mutated metastatic melanoma. <i>Drugs in Context</i> , 2021, 10, 1-6.	1.0	1
327	Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial. <i>Frontiers in Oncology</i> , 2021, 11, 720044.	1.3	9
328	Medication guide for the perioperative management of oral antineoplastic agents in cancer patients. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 107-119.	1.0	2
329	Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2914-2925.	0.8	55
330	The Functional Role of Long Non-Coding RNAs in Melanoma. <i>Cancers</i> , 2021, 13, 4848.	1.7	11
331	Atezolizumab plus vemurafenib and cobimetinib for the treatment of BRAF V600-mutant advanced melanoma: from an hypothetic triplet to an approved regimen. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 349-360.	0.4	0
332	Management of Pyrexia Associated with the Combination of Dabrafenib and Trametinib: Canadian Consensus Statements. <i>Current Oncology</i> , 2021, 28, 3537-3553.	0.9	5
333	Small-Molecule Anti-Cancer Drugs From 2016 to 2020: Synthesis and Clinical Application. <i>Natural Product Communications</i> , 2021, 16, 1934578X2110403.	0.2	2
334	Molecular Markers and Targets in Melanoma. <i>Cells</i> , 2021, 10, 2320.	1.8	72
335	Which adjuvant treatment for patients with BRAFV600-mutant cutaneous melanoma?. <i>Annales De Dermatologie Et De Venereologie</i> , 2021, 148, 145-155.	0.5	4
336	Diagnosis and treatment of hairy cell leukemia as the COVID-19 pandemic continues. <i>Blood Reviews</i> , 2022, 51, 100888.	2.8	4
337	Targeting BRAF Activation as Acquired Resistance Mechanism to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small-Cell Lung Cancer. <i>Pharmaceutics</i> , 2021, 13, 1478.	2.0	9
338	Dermatologic adverse events associated with targeted therapies for melanoma. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 385-395.	1.0	0
339	Emerging Therapies in the Treatment of Advanced Melanoma. <i>Clinics in Plastic Surgery</i> , 2021, 48, 713-733.	0.7	3
340	Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors. <i>Cancer Treatment Reviews</i> , 2021, 100, 102282.	3.4	25
341	Encorafenib/binimetinib induced severe liver injury in a melanoma patient: Case report and review of literature. <i>Current Problems in Cancer Case Reports</i> , 2021, 4, 100086.	0.1	0
342	Clinical considerations of CDK4/6 inhibitors in triple-negative breast cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188590.	3.3	17
343	Current Advancements and Novel Strategies in the Treatment of Metastatic Melanoma. <i>Integrative Cancer Therapies</i> , 2021, 20, 153473542199007.	0.8	25

#	ARTICLE	IF	CITATIONS
344	The combination of encorafenib and binimetinib for the treatment of patients with BRAF-mutated advanced, unresectable, or metastatic melanoma: an update. Expert Review of Precision Medicine and Drug Development, 2021, 6, 19-29.	0.4	3
345	An Overview of Liver Directed Locoregional Therapies. Surgical Oncology Clinics of North America, 2021, 30, 103-123.	0.6	8
347	Overview of Current Type I/II Kinase Inhibitors. , 2020, , 13-28.		8
348	Sequencing and Combinations of Molecularly Targeted and Immunotherapy for BRAF-Mutant Melanoma. , 2019, , 1-27.		1
349	KIT as an Oncogenic Driver in Melanoma: An Update on Clinical Development. American Journal of Clinical Dermatology, 2019, 20, 315-323.	3.3	64
350	Cooperativity Between Orthosteric Inhibitors and Allosteric Inhibitor 8-Anilino-1-Naphthalene Sulfonic Acid (ANS) in Cyclin-Dependent Kinase 2. ACS Chemical Biology, 2020, 15, 1759-1764.	1.6	9
351	Adult precision medicine: learning from the past to enhance the future. Neuro-Oncology Advances, 2021, 3, vdaa145.	0.4	11
352	Case report: acute tumour lysis syndrome following encorafenib and binimetinib for v600E metastatic melanoma with large intra-abdominal mass. Melanoma Research, 2020, 30, 625-627.	0.6	5
354	Efficient blockade of locally reciprocated tumor-macrophage signaling using a TAM-avid nanotherapy. Science Advances, 2020, 6, eaaz8521.	4.7	22
355	A new B-Raf inhibitor combo for advanced melanoma. Oncotarget, 2018, 9, 34457-34458.	0.8	2
356	Tris DBA palladium is an orally available inhibitor of GNAQ mutant uveal melanoma <i>in vivo</i> . Oncotarget, 2019, 10, 4424-4436.	0.8	7
357	New drug: Binimetinib plus encorafenib for metastatic melanoma. Australian Prescriber, 2019, 42, 168-168.	0.5	2
358	Evolution of Molecular Targets in Melanoma Treatment. Current Pharmaceutical Design, 2020, 26, 396-414.	0.9	10
359	The Systemic Treatment of Melanoma: The Place of Immune Checkpoint Inhibitors and the Suppression of Intracellular Signal Transduction. Deutsches Ärztblatt International, 2019, 116, 497-504.	0.6	15
360	Identification of Genetic Mutations in Cancer: Challenge and Opportunity in the New Era of Targeted Therapy. Frontiers in Oncology, 2019, 9, 263.	1.3	62
361	Diretriz Brasileira de Cardio-oncologia â€œ 2020. Arquivos Brasileiros De Cardiologia, 2020, 115, 1006-1043.	0.3	37
362	Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 367-402.	2.3	326
363	NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 364-376.	2.3	167

#	ARTICLE	IF	CITATIONS
364	Cutaneous Melanoma and Other Skin Cancers. UNIPA Springer Series, 2021, , 979-1007.	0.1	0
365	Vemurafenib Drives Epithelial-to-Mesenchymal Transition Gene Expression in BRAF Inhibitor-Resistant BRAFV600E/NRASQ61K Melanoma Enhancing Tumor Growth and Metastasis in a Bioluminescent Murine Model. Journal of Investigative Dermatology, 2022, 142, 1456-1465.e1.	0.3	7
366	Disease-Associated Risk Variants in <i>ANRIL</i> Are Associated with Tumor-Infiltrating Lymphocyte Presence in Primary Melanomas in the Population-Based GEM Study. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 2309-2316.	1.1	2
367	Antitumor Activity of Ipilimumab or BRAF ± MEK Inhibition After Pembrolizumab in Patients With Advanced Melanoma: Analysis from KEYNOTE-006. Annals of Oncology, 2021, , .	0.6	5
369	Dedifferentiated Melanoma: A Diagnostic Histological Pitfall—Review of the Literature with Case Presentation. Dermatopathology (Basel, Switzerland), 2021, 8, 494-501.	0.7	8
370	Genomic sequencing to inform therapy in advanced pancreatic cancer: A systematic review and meta-analysis of prospective studies. Cancer Treatment Reviews, 2021, 101, 102310.	3.4	2
371	PET Imaging of VLA-4 in a New BRAFV600E Mouse Model of Melanoma. Molecular Imaging and Biology, 2022, 24, 425-433.	1.3	3
372	Nanotechnology Addressing Cutaneous Melanoma: The Italian Landscape. Pharmaceutics, 2021, 13, 1617.	2.0	11
373	Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAFV600 mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trial. European Journal of Cancer, 2021, 158, 72-84.	1.3	14
374			

#	ARTICLE	IF	CITATIONS
387	Melanom. , 2019, , 45-134.		0
388	Emerging Novel Therapies in Overcoming Resistance to Targeted Therapy. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 223-258.	0.1	0
390	Neurological Complications of Targeted Therapies. , 2020, , 341-363.		0
391	Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Cutaneous Melanoma. Recent Patents on Anti-Cancer Drug Discovery, 2019, 14, 203-225.	0.8	1
393	Adjuvant Systemic Therapy for High-Risk Melanoma Patients. , 2020, , 747-766.		0
394	Dermatological Complications of Systemic Therapies for Melanoma. , 2020, , 1337-1358.		0
395	Harnessing the predictive power of preclinical models for oncology drug development. Nature Reviews Drug Discovery, 2022, 21, 99-114.	21.5	41
396	BRAF inhibition and the spectrum of granulomatous reactions. Journal of the American Academy of Dermatology, 2021, , .	0.6	5
397	Role of Isolated Limb Perfusion in the Era of Targeted Therapies and Immunotherapy in Melanoma. A Systematic Review of The Literature. Cancers, 2021, 13, 5485.	1.7	4
398	MAPK blockade, toxicities, pathogenesis and management. Current Opinion in Oncology, 2021, 33, 139-145.	1.1	3
399	Neoadjuvant and Adjuvant Approach Treatment of B-RAF Positive Limited Metastatic Melanoma. SunText Review of Medical & Clinical Research, 2020, 01, .	0.1	0
400	Sequencing and Combinations of Molecularly Targeted and Immunotherapy for BRAF-Mutant Melanoma. , 2020, , 1215-1241.		0
401	Indirect Comparison of Combined BRAF and MEK Inhibition in Melanoma Patients with Elevated Baseline Lactate Dehydrogenase. Acta Dermato-Venereologica, 2020, 100, adv00174.	0.6	0
402	Melanoma Brain Metastases: Unique Biology and Implications for Systemic Therapy. , 2020, , 1421-1454.		0
403	Targeted Therapies for BRAF-Mutant Metastatic Melanoma. , 2020, , 1067-1085.		0
404	Pharmacogenomics of Antitumor Targeted Agent and Immunotherapy. , 2020, , 55-82.		0
405	Integrating Systemic Therapy into the Management of Brain Metastases. , 2020, , 95-108.		0
406	Non-melanoma Skin Cancer and Cutaneous Melanoma from the Oncological Point of View. , 2020, , 41-68.		0

#	ARTICLE	IF	CITATIONS
407	Individualized Treatment Strategy for Cutaneous Melanoma: Where Are We Now and Where Are We Going?. <i>Frontiers in Oncology</i> , 2021, 11, 775100.	1.3	6
408	Emerging Developments in Management of Melanoma During the COVID-19 Era. <i>Frontiers in Medicine</i> , 2021, 8, 769368.	1.2	2
409	BRAF Signaling Inhibition in Glioblastoma: Which Clinical Perspectives?. <i>Frontiers in Oncology</i> , 2021, 11, 772052.	1.3	18
411	Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastases. <i>Melanoma Research</i> , 2021, 31, 58-66.	0.6	6
412	Economic Burden of Adverse Events Associated with Immunotherapy and Targeted Therapy for Metastatic Melanoma in the Elderly. <i>American Health and Drug Benefits</i> , 2018, 11, 334-343.	0.5	6
413	High-throughput ex vivo drug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma. <i>Translational Oncology</i> , 2022, 15, 101290.	1.7	4
414	Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies. <i>Current Oncology</i> , 2021, 28, 4894-4928.	0.9	0
415	Clinical Significance of Distant Metastasis-Free Survival (DMFS) in Melanoma: A Narrative Review from Adjuvant Clinical Trials. <i>Journal of Clinical Medicine</i> , 2021, 10, 5475.	1.0	8
416	Melanoma Targeted Therapies beyond BRAF-Mutant Melanoma: Potential Druggable Mutations and Novel Treatment Approaches. <i>Cancers</i> , 2021, 13, 5847.	1.7	16
417	Optimal surveillance strategies for patients with stage 1 cutaneous melanoma post primary tumour excision: three systematic reviews and an economic model. <i>Health Technology Assessment</i> , 2021, 25, 1-178.	1.3	4
418	Targeted therapy strategies for melanoma brain metastasis. <i>Neuro-Oncology Advances</i> , 2021, 3, v75-v85.	0.4	3
419	Pharmacogenomics in solid cancers and hematologic malignancies: improving personalized drug prescription. <i>Therapie</i> , 2021, , .	0.6	1
420	Adjuvant Pembrolizumab versus IFN γ 2b or Ipilimumab in Resected High-Risk Melanoma. <i>Cancer Discovery</i> , 2022, 12, 644-653.	7.7	32
421	Molecular Alterations Associated with Acquired Drug Resistance during Combined Treatment with Encorafenib and Binimetinib in Melanoma Cell Lines. <i>Cancers</i> , 2021, 13, 6058.	1.7	7
422	Fine-tuning of MEK signaling is pivotal for limiting B and T cell activation. <i>Cell Reports</i> , 2022, 38, 110223.	2.9	3
423	Nuclear PD-L1 promotes cell cycle progression of BRAF-mutated colorectal cancer by inhibiting THRAP3. <i>Cancer Letters</i> , 2022, 527, 127-139.	3.2	18
424	Fortgeschrittenes malignes Melanom: Kernpunkte der aktualisierten Leitlinie. , 0, , .		0
425	Signal pathways of melanoma and targeted therapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 424.	7.1	115

#	ARTICLE	IF	CITATIONS
426	Clinical Trial Eligibility Criteria and Recently Approved Cancer Therapies for Patients With Brain Metastases. <i>Frontiers in Oncology</i> , 2021, 11, 780379.	1.3	7
427	Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). <i>Annals of Surgical Oncology</i> , 2022, 29, 3694-3708.	0.7	21
428	Targeting Oncogenic Pathways in the Era of Personalized Oncology: A Systemic Analysis Reveals Highly Mutated Signaling Pathways in Cancer Patients and Potential Therapeutic Targets. <i>Cancers</i> , 2022, 14, 664.	1.7	7
429	The Predictive Value of MAP2K1/2 Mutations on Efficiency of Immunotherapy in Melanoma. <i>Frontiers in Immunology</i> , 2021, 12, 785526.	2.2	6
430	Medication adherence reporting in pivotal clinical trials: overview of oral oncological drugs. <i>European Journal of Hospital Pharmacy</i> , 2023, 30, 328-332.	0.5	4
431	BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600 <i>i</i> -mutant Melanoma. <i>Clinical Cancer Research</i> , 2022, 28, 1098-1106.	3.2	32
432	2,2-Dichloro-N-[5-[2-[3-(4-methoxyphenyl)-5-phenyl-3,4-dihydro-2H-pyrazol-2-yl]-2-oxoethyl]sulfanyl-1,3,4-thiadiazol-2-yl]acetamide. <i>MolBank</i> , 2022, 2022, M1328.	0.2	2
433	New Therapeutic Approaches for Conjunctival Melanoma—What We Know So Far and Where Therapy Is Potentially Heading: Focus on Lymphatic Vessels and Dendritic Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1478.	1.8	4
434	Therapeutic Opportunities of Disrupting Genome Integrity in Adult Diffuse Glioma. <i>Biomedicines</i> , 2022, 10, 332.	1.4	0
435	Recent progress of research on anti-tumor agents using benzimidazole as the structure unit. <i>Chemical Biology and Drug Design</i> , 2022, 99, 736-757.	1.5	14
437	New Approaches with Precision Medicine in Adult Brain Tumors. <i>Cancers</i> , 2022, 14, 712.	1.7	2
438	Plasma Thymidine Kinase Activity as a Novel Biomarker in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2022, 14, 702.	1.7	3
439	BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting. <i>Pathology</i> , 2022, 54, 6-19.	0.3	3
440	Recent advances in B-RAF inhibitors as anticancer agents. <i>Bioorganic Chemistry</i> , 2022, 120, 105597.	2.0	10
441	Circulating Tumour DNA in Melanoma—Clinic Ready?. <i>Current Oncology Reports</i> , 2022, 24, 363-373.	1.8	10
442	Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma. <i>Journal of Clinical Medicine</i> , 2022, 11, 828.	1.0	10
443	Efficacy of BRAF inhibitor and anti-EGFR antibody in colorectal neuroendocrine carcinoma. <i>Clinical Journal of Gastroenterology</i> , 2022, 15, 413-418.	0.4	7
444	Beyondcell: targeting cancer therapeutic heterogeneity in single-cell RNA-seq data. <i>Genome Medicine</i> , 2021, 13, 187.	3.6	25

#	ARTICLE	IF	CITATIONS
445	Oxidative Stress-Related Mechanisms in Melanoma and in the Acquired Resistance to Targeted Therapies. <i>Antioxidants</i> , 2021, 10, 1942.	2.2	33
447	Neurological complications of GI cancers. , 2022, , 365-386.		0
448	Biology and pathophysiology of central nervous system metastases. , 2022, , 55-78.		0
451	Cardiotoxicity of Systemic Melanoma Treatments. <i>Current Treatment Options in Oncology</i> , 2022, 23, 240-253.	1.3	2
452	Response to BRAF and MEK Inhibitors in BRAF Thr599dupâ€“Mutated Melanoma. <i>JCO Precision Oncology</i> , 2022, 6, e2100417.	1.5	1
453	Inhibition of Axl Promotes the Therapeutic Effect of Targeted Inhibition of the PI3K/Akt Pathway in NRAS Mutant Melanoma Cells. <i>Journal of Oncology</i> , 2022, 2022, 1-9.	0.6	2
454	Real-World Evidence of Systemic Therapy Sequencing on Overall Survival for Patients with Metastatic BRAF-Mutated Cutaneous Melanoma. <i>Current Oncology</i> , 2022, 29, 1501-1513.	0.9	0
455	BRAF inhibitors and their immunological effects in malignant melanoma. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 347-362.	1.3	8
456	The Interplay between Tumour Microenvironment Components in Malignant Melanoma. <i>Medicina (Lithuania)</i> , 2022, 58, 365.	0.8	8
457	Encorafenib plus binimetinib in patients with <i>BRAF</i> ^{V600} -mutant non-smallâ€“cell lung cancer: phase II PHAROS study design. <i>Future Oncology</i> , 2022, 18, 781-791.	1.1	9
458	The Current State of Treatment and Future Directions in Cutaneous Malignant Melanoma. <i>Biomedicines</i> , 2022, 10, 822.	1.4	18
460	Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEKâ€“Inhibitors. <i>JACC: CardioOncology</i> , 2022, 4, 1-18.	1.7	18
461	Cardiovascular disease and malignant melanoma. <i>Melanoma Research</i> , 2022, Publish Ahead of Print, .	0.6	3
462	Severe treatment-induced inflammatory polyarthritis in advanced melanoma patients: 2 case reports. <i>Melanoma Research</i> , 2022, Publish Ahead of Print, .	0.6	1
463	Intermittent treatment of BRAF ^{V600E} melanoma cells delays resistance by adaptive resensitization to drug rechallenge. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2113535119.	3.3	20
464	FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021. <i>Molecules</i> , 2022, 27, 2259.	1.7	14
465	Novel chloroquine derivative suppresses melanoma cell growth by DNA damage through increasing ROS levels. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 2579-2593.	1.6	2
466	Targeted Therapy for Melanomas Without BRAF V600 Mutations. <i>Current Treatment Options in Oncology</i> , 2022, 23, 831-842.	1.3	8

#	ARTICLE	IF	CITATIONS
467	Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy. <i>Cell Reports</i> , 2022, 39, 110634.	2.9	10
468	Neoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and Timing. <i>BioDrugs</i> , 2022, 36, 373-380.	2.2	2
469	Morusin enhances the antitumor activity of MAPK pathway inhibitors in BRAF-mutant melanoma by inhibiting the feedback activation of STAT3. <i>European Journal of Cancer</i> , 2022, 165, 58-70.	1.3	7
470	Triplet Therapy in Melanoma – Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies. <i>Current Oncology Reports</i> , 2022, 24, 1071-1079.	1.8	11
471	MEK inhibitors for pre-treated, NRAS-mutated metastatic melanoma: A multi-centre, retrospective study. <i>European Journal of Cancer</i> , 2022, 166, 24-32.	1.3	10
472	Theragnostic significance of tumor-infiltrating lymphocytes and Ki67 in BRAFV600-mutant metastatic melanoma (BRIM-3 trial). <i>Current Problems in Cancer</i> , 2022, 46, 100862.	1.0	3
473	Case report of a patient with metastatic melanoma treated with several lines of systemic treatment. <i>Onkologie (Czech Republic)</i> , 2021, 15, 179-181.	0.0	0
474	Recent Developments in Targeting RAS Downstream Effectors for RAS-Driven Cancer Therapy. <i>Molecules</i> , 2021, 26, 7561.	1.7	3
475	Targeting AVIL, a New Cytoskeleton Regulator in Glioblastoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13635.	1.8	4
476	Plexiform neurofibroma: shedding light on the investigational agents in clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 31-40.	1.9	1
477	Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma. <i>Neuro-Oncology</i> , 2022, 24, 1964-1975.	0.6	15
478	Organocatalytic atroposelective construction of axially chiral N, N- and N, S-1,2-azoles through novel ring formation approach. <i>Nature Communications</i> , 2022, 13, 1933.	5.8	28
479	Targeting mutations in cancer. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	56
497	Characterization of anticancer drug resistance by reverse-phase protein array: new targets and strategies. <i>Expert Review of Proteomics</i> , 2022, 19, 115-129.	1.3	3
498	Should Targeted Therapy Be Continued in BRAF-Mutant Melanoma Patients after Complete Remission?. <i>Dermatology</i> , 2022, 238, 517-526.	0.9	5
499	Erythema multiforme-like rash upon anti-melanoma therapy with BRAF and MEK inhibitors. <i>European Journal of Dermatology</i> , 2019, 29, 107-108.	0.3	1
501	Melanoma: An immunotherapy journey from bench to bedside. <i>Cancer Treatment and Research</i> , 2022, 183, 49-89.	0.2	0
502	Improved overall survival in dual compared to single immune checkpoint inhibitors in BRAF V600-negative advanced melanoma. <i>Melanoma Management</i> , 2022, 9, MMT60.	0.1	1

#	ARTICLE	IF	CITATIONS
503	Progressing Vulvar Melanoma Caused by Instability in cKIT Juxtamembrane Domain: A Case Report and Review of Literature. <i>Current Oncology</i> , 2022, 29, 3130-3137.	0.9	1
504	Overcoming differential tumor penetration of BRAF inhibitors using computationally guided combination therapy. <i>Science Advances</i> , 2022, 8, eabl6339.	4.7	6
505	The Role of Treatment Sequencing with Immune-Checkpoint Inhibitors and BRAF/MEK Inhibitors for Response and Survival of Patients with BRAFV600-Mutant Metastatic Melanoma—A Retrospective, Real-World Cohort Study. <i>Cancers</i> , 2022, 14, 2082.	1.7	9
506	Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients. <i>Cancers</i> , 2022, 14, 2123.	1.7	2
507	Molecular Pathways and Mechanisms of BRAF in Cancer Therapy. <i>Clinical Cancer Research</i> , 2022, 28, 4618-4628.	3.2	37
508	Discovery of Raf Family Is a Milestone in Deciphering the Ras-Mediated Intracellular Signaling Pathway. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5158.	1.8	16
509	Adjuvant and Neoadjuvant Therapies in Cutaneous Melanoma. <i>Oral and Maxillofacial Surgery Clinics of North America</i> , 2022, 34, 315-324.	0.4	2
510	Sex and Gender Differences in Anticancer Treatment Toxicity: A Call for Revisiting Drug Dosing in Oncology. <i>Endocrinology</i> , 2022, 163, .	1.4	21
511	The future of targeted kinase inhibitors in melanoma. , 2022, 239, 108200.		17
513	Double Trouble: Immunotherapy Doublets in Melanoma—Approved and Novel Combinations to Optimize Treatment in Advanced Melanoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 745-766.	1.8	6
514	Immune-mediated necrotizing myopathy with anti-signal recognition particle antibodies, in a patient with melanoma treated with BRAF/MEK inhibitors. <i>Melanoma Research</i> , 0, Publish Ahead of Print, .	0.6	1
515	Precision radiation of immune checkpoint therapy resistant melanoma metastases (PROMMEL study): study protocol for a phase II open-label multicenter trial. <i>Acta Oncologica</i> , 2022, 61, 869-873.	0.8	1
516	A Case of Pulmonary Sarcoidosis during First-Line Targeted Therapy with Dabrafenib Plus Trametinib in <i>BRAF</i> V600E-Mutated Metastatic Melanoma. <i>Case Reports in Oncology</i> , 2022, 15, 560-565.	0.3	3
517	Encorafenib and Binimetinib Combination Therapy in Metastatic Melanoma. <i>Journal of the Advanced Practitioner in Oncology</i> , 2022, 13, 450-455.	0.2	11
518	Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions. <i>Lung Cancer</i> , 2022, 169, 102-114.	0.9	8
519	European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022. <i>European Journal of Cancer</i> , 2022, 170, 256-284.	1.3	92
520	A phase I study of the safety and efficacy of talimogene laherparepvec in Japanese patients with advanced melanoma. <i>Cancer Science</i> , 0, , .	1.7	4
521	Cardiovascular risks of chemotherapy. , 2023, , 20-35.		0

#	ARTICLE	IF	CITATIONS
522	Cutaneous melanoma. , 2023, , 370-375.		0
524	Treatment Approaches for Melanomas That Relapse After Adjuvant or Neoadjuvant Therapy. Current Oncology Reports, 2022, 24, 1273-1280.	1.8	5
525	Cross-Resistance Among Sequential Cancer Therapeutics: An Emerging Issue. Frontiers in Oncology, 0, 12, .	1.3	8
526	Combination of Whole-Body Baseline CT Radiomics and Clinical Parameters to Predict Response and Survival in a Stage-IV Melanoma Cohort Undergoing Immunotherapy. Cancers, 2022, 14, 2992.	1.7	12
527	Severe Inflammatory Colitis Related to Encorafenib and Binimetinib following Immune Checkpoint Inhibitor Therapy. Case Reports in Gastroenterology, 2022, 16, 388-393.	0.3	2
528	A Decade of Success in Melanoma Immunotherapy and Targeted Therapy: What Every Radiologist Should Know. Journal of Computer Assisted Tomography, 2022, 46, 621-632.	0.5	2
529	Impact of Previous Local Treatment for Brain Metastases on Response to Molecular Targeted Therapy in BRAF-Mutant Melanoma Brain Metastasis: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 0, 12, .	1.3	0
530	Symptomatic melanoma metastases in the brain: are we using all therapy options?. Meditsinskiy Sovet, 2022, , 66-74.	0.1	0
531	Targeting the Epigenome in Malignant Melanoma: Facts, Challenges and Therapeutic Promises. SSRN Electronic Journal, 0, , .	0.4	0
532	Immunotherapy of Metastatic Melanoma. , 0, , .		0
533	The Value of Histopathological Characteristics and BRAF and NRAS Mutations for the Diagnosis, Risk Stratification, and Prognosis of Malignant Invasive Melanoma. , 0, , .		0
534	The Evolution of BRAF Activation in Non-Small-Cell Lung Cancer. Frontiers in Oncology, 0, 12, .	1.3	8
536	CCND1 Amplification Profiling Identifies a Subtype of Melanoma Associated With Poor Survival and an Immunosuppressive Tumor Microenvironment. Frontiers in Immunology, 0, 13, .	2.2	6
537	COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With<i>BRAF</i>V600â€“Mutant Melanoma. Journal of Clinical Oncology, 2022, 40, 4178-4188.	0.8	57
538	Proliferation and Immune Response Gene Signatures Associated with Clinical Outcome to Immunotherapy and Targeted Therapy in Metastatic Cutaneous Malignant Melanoma. Cancers, 2022, 14, 3587.	1.7	6
539	Treatment reality of patients with BRAF-mutant advanced/metastatic melanoma in Switzerland in the era of choice. Melanoma Research, 0, Publish Ahead of Print, .	0.6	1
540	No needles needed: All-oral therapy options for relapsed & refractory multiple myeloma. Blood Reviews, 2022, , 100993.	2.8	0
541	Anti-cancer drug combinations approved by US FDA from 2011 to 2021: main design features of clinical trials and role of pharmacokinetics. Cancer Chemotherapy and Pharmacology, 2022, 90, 285-299.	1.1	4

#	ARTICLE	IF	CITATIONS
542	Molecular mechanisms of resistance to kinase inhibitors in thyroid cancers. <i>Endocrine-Related Cancer</i> , 2022, , .	1.6	4
543	Optimized scaling of translational factors in oncology: from xenografts to RECIST. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 90, 239-250.	1.1	1
544	Simultaneous Generation of Methyl Esters and CO in Lignin Transformation. <i>Angewandte Chemie - International Edition</i> , 2022, 61, .	7.2	7
545	The Role of PKC-MAPK Signalling Pathways in the Development of Hyperglycemia-Induced Cardiovascular Complications. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8582.	1.8	17
546	Simultaneous Generation of Methyl Esters and CO in Lignin Transformation. <i>Angewandte Chemie</i> , 0, , .	1.6	0
547	Teaching NeuroImage: Horizontal Diplopia Due to Extraocular Muscle Metastasis. <i>Neurology</i> , 2022, 99, 669-670.	1.5	0
548	Genomic and Transcriptomic Analyses of NF1-Mutant Melanoma Identify Potential Targeted Approach for Treatment. <i>Journal of Investigative Dermatology</i> , 2023, 143, 444-455.e8.	0.3	5
549	Treatment of Metastatic Melanoma at First Diagnosis: Review of the Literature. <i>Life</i> , 2022, 12, 1302.	1.1	5
550	Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Melanoma in the United States: An Analysis Using Long-Term Overall Survival Data from Checkmate 067. <i>PharmacoEconomics - Open</i> , 2022, 6, 697-710.	0.9	3
551	BRAF Mutations in Colorectal Liver Metastases: Prognostic Implications and Potential Therapeutic Strategies. <i>Cancers</i> , 2022, 14, 4067.	1.7	5
552	Evidence from Clinical Studies Related to Dermatologic Surgeries for Skin Cancer. <i>Cancers</i> , 2022, 14, 3835.	1.7	3
553	Dynamics of plasma thymidine kinase activity in metastatic melanoma reflects immune checkpoint inhibitor efficacy. <i>Acta Oncol</i> , 2022, 61, 1116-1120.	0.8	2
554	Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis. <i>Cancer Treatment Reviews</i> , 2022, 110, 102463.	3.4	10
555	Diagnostic Applications of Nuclear Medicine: Malignant Melanoma. , 2022, , 1235-1269.		0
556	Substanzen gegen molekulare Zielstrukturen. <i>Springer Reference Medizin</i> , 2022, , 1-14.	0.0	0
557	UV-Induced Somatic Mutations Driving Clonal Evolution in Healthy Skin, Nevus, and Cutaneous Melanoma. <i>Life</i> , 2022, 12, 1339.	1.1	7
558	Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated <i>BRAF</i>-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial. <i>Journal of Clinical Oncology</i> , 2023, 41, 212-221.	0.8	76
559	Combined Focused Next-Generation Sequencing Assays to Guide Precision Oncology in Solid Tumors: A Retrospective Analysis from an Institutional Molecular Tumor Board. <i>Cancers</i> , 2022, 14, 4430.	1.7	7

#	ARTICLE	IF	CITATIONS
560	First-line pembrolizumab versus dabrafenib/trametinib treatment for BRAF V600a€‘mutant advanced melanoma. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 989-996.	0.6	3
561	NAD/NAMPT and mTOR Pathways in Melanoma: Drivers of Drug Resistance and Prospective Therapeutic Targets. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9985.	1.8	11
562	Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis. <i>Cancer Research</i> , 2022, 82, 4261-4273.	0.4	8
563	Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?. <i>Annals of Surgical Oncology</i> , 2023, 30, 573-586.	0.7	1
564	A Japanese case of melanoma of unknown origin with a rare <i><sup>>V600R</sup></i> mutation was successfully treated with BRAF/MEK inhibitors. <i>Drug Discoveries and Therapeutics</i> , 2022, 16, 256-257.	0.6	1
565	Identification of a miRNA-based non-invasive predictive biomarker of response to target therapy in BRAF-mutant melanoma. <i>Theranostics</i> , 2022, 12, 7420-7430.	4.6	10
567	Gut Microbiota and Therapy in Metastatic Melanoma: Focus on MAPK Pathway Inhibition. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11990.	1.8	1
568	Targeted Therapy and Immunotherapy in Melanoma. <i>Dermatologic Clinics</i> , 2023, 41, 65-77.	1.0	14
569	Integrating a Comprehensive Cancer Genome Profiling into Clinical Practice: A Blueprint in an Italian Referral Center. <i>Journal of Personalized Medicine</i> , 2022, 12, 1746.	1.1	5
570	SRC-RAC1 signaling drives drug resistance to BRAF inhibition in de-differentiated cutaneous melanomas. <i>Npj Precision Oncology</i> , 2022, 6, .	2.3	5
571	BRAF Inhibitors in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 4863.	1.7	4
572	Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	59
573	Minor structural changes, major functional impacts: posttranslational modifications and drug targets. <i>Archives of Pharmacal Research</i> , 0, , .	2.7	0
574	Immune Checkpoint Inhibitors and RASa€‘ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma. <i>Biomolecules</i> , 2022, 12, 1562.	1.8	5
575	EGFR pathway targeting drugs in head and neck cancer in the era of immunotherapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2023, 1878, 188827.	3.3	7
577	The <sc>AhR</sc> axis as a therapeutic vulnerability in <sc>BRAFi</sc>a€‘resistant melanoma. <i>EMBO Molecular Medicine</i> , 2022, 14, .	3.3	8
579	Small molecule inhibitors targeting the cancers. <i>MedComm</i> , 2022, 3, .	3.1	25
580	Melanoma classification and management in the era of molecular medicine. <i>Dermatologic Clinics</i> , 2023, 41, 49-63.	1.0	15

#	ARTICLE	IF	CITATIONS
582	Targeting the epigenome in malignant melanoma: Facts, challenges and therapeutic promises. , 2022, 240, 108301.		9
583	Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer: an early post-marketing phase vigilance study. International Journal of Clinical Oncology, 2023, 28, 139-144.	1.0	2
584	Tissue-resident memory T cells in the era of (Neo) adjuvant melanoma management. Frontiers in Immunology, 0, 13, .	2.2	5
585	Insights into the aberrant CDK4/6 signaling pathway as a therapeutic target in tumorigenesis. Advances in Protein Chemistry and Structural Biology, 2023, , 179-201.	1.0	4
586	BRAF Testing in Melanoma and Colorectal Cancer in Latin America: Challenges and Opportunities. Cureus, 2022, , .	0.2	0
587	Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trial. BMJ Open, 2022, 12, e063700.	0.8	0
588	Effects of BRAF V600E and NRAS mutational status on the progression-free survival and clinicopathological characteristics of patients with melanoma. Oncology Letters, 2022, 25, .	0.8	9
589	BRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis. Cancers, 2023, 15, 141.	1.7	14
590	Adverse events associated with encorafenib plus cetuximab in patients with BRAFV600E-mutant metastatic colorectal cancer: an in-depth analysis of the BEACON CRC study. Clinical Colorectal Cancer, 2022, , .	1.0	4
591	New prospectives on treatment opportunities in <scp>RASopathies</scp>. American Journal of Medical Genetics, Part C: Seminars in Medical Genetics, 2022, 190, 541-560.	0.7	4
592	Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 2022, 387, 2113-2125.	13.9	120
593	Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response Rates. International Journal of Molecular Sciences, 2023, 24, 41.	1.8	6
595	Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases. Clinical Cancer Research, 2023, 29, 521-531.	3.2	5
596	Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. , 2022, 10, e005755.		34
597	Changes in outcomes and factors associated with survival in melanoma patients with brain metastases. Neuro-Oncology, 2023, 25, 1310-1320.	0.6	5
599	Emerging Role of Targeted Therapy in Metastatic Pancreatic Adenocarcinoma. Cancers, 2022, 14, 6223.	1.7	6
600	Melanogenesis and the Targeted Therapy of Melanoma. Biomolecules, 2022, 12, 1874.	1.8	9
601	Spinal Metastases and the Evolving Role of Molecular Targeted Therapy, Chemotherapy, and Immunotherapy. Neurospine, 2022, 19, 978-993.	1.1	3

#	ARTICLE	IF	CITATIONS
602	Discovery of a Novel ATP-Competitive MEK Inhibitor DS03090629 that Overcomes Resistance Conferred by BRAF Overexpression in BRAF-Mutated Melanoma. <i>Molecular Cancer Therapeutics</i> , 2023, 22, 317-332.	1.9	2
603	Phytochemical Constituents and Derivatives of <i>Cannabis sativa</i> ; Bridging the Gap in Melanoma Treatment. <i>International Journal of Molecular Sciences</i> , 2023, 24, 859.	1.8	8
604	Real-world treatment patterns and outcomes in patients with metastatic melanoma. <i>Srpski Arhiv Za Celokupno Lekarstvo</i> , 2023, , 6-6.	0.1	0
605	Economic Evaluation of Three BRAF + MEK Inhibitors for the Treatment of Advanced Unresectable Melanoma With BRAF Mutation From a US Payer Perspective. <i>Annals of Pharmacotherapy</i> , 0, , 106002802211468.	0.9	1
606	BRAF gene as a potential target to attenuate drug resistance and treat cancer. <i>Gene Reports</i> , 2023, 30, 101740.	0.4	1
607	Severe colitis in patients with melanoma treated with <scp>BRAF</scp>/<scp>MEK</scp> inhibitors. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 792-799.	1.9	3
608	MAPK Pathway Inhibitors in Thyroid Cancer: Preclinical and Clinical Data. <i>Cancers</i> , 2023, 15, 710.	1.7	11
609	Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive BRAF Mutant Advanced Melanoma. <i>Biomedicines</i> , 2023, 11, 394.	1.4	0
610	KutanĀız Malign Melanom Nedeniyle Takip EttiĀyimiz HastalarĀn Klinikopatolojik Āzellikleri. <i>Turkish Journal of Clinics and Laboratory</i> , 0, , .	0.2	0
611	Epidemiology, management, and treatment outcomes of metastatic spinal melanoma. <i>World Neurosurgery: X</i> , 2023, 18, 100156.	0.6	1
612	PiperineĀChlorogenic Acid Hybrid Inhibits the Proliferation of the SK-MEL-147 Melanoma Cells by Modulating Mitotic Kinases. <i>Pharmaceuticals</i> , 2023, 16, 145.	1.7	5
613	Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	6
614	Checkpoint blockade and <scp>BRAF</scp>/<scp>MEK</scp> therapy in the therapeutic setting improved the overall survival after sentinel node biopsy: A retrospective study comparing patients with primary care between 1998Ā2009 and 2010Ā2017. <i>International Journal of Cancer</i> , 2023, 153, 380-388.	2.3	0
615	Melanoma metastatic to the adrenal gland: An update on the role of adrenalectomy in multidisciplinary management. <i>Journal of Surgical Oncology</i> , 2023, 128, 313-321.	0.8	2
616	Combination of immune-checkpoint inhibitors and targeted therapies for melanoma therapy: The more, the better?. <i>Cancer and Metastasis Reviews</i> , 2023, 42, 481-505.	2.7	2
617	Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy. <i>ESMO Open</i> , 2023, 8, 100788.	2.0	22
618	Melanome der Haut und Schleimhaut. , 2022, , 205-236.		0
619	Brain Metastases from Biliary Tract Cancer: Case Series and Clinicogenomic Analysis. <i>Oncologist</i> , 2023, 28, 327-332.	1.9	0

#	ARTICLE	IF	CITATIONS
620	Targeting EphA2 and DDR signaling can overcome the BRAF and MEK inhibitors acquired resistance in melanoma cell lines. <i>Translational Medicine Communications</i> , 2023, 8, .	0.5	2
621	Common toxicities associated with immune checkpoint inhibitors and targeted therapy in the treatment of melanoma: A systematic scoping review. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 183, 103919.	2.0	3
622	Helper Innate Lymphoid Cells—Unappreciated Players in Melanoma Therapy. <i>Cancers</i> , 2023, 15, 933.	1.7	1
623	Assessment of Retinal Pigment Epithelium Alterations and Chorioretinal Vascular Network Analyses in Patients under Treatment with BRAF/MEK Inhibitor for Different Malignancies: A Pilot Study. <i>Journal of Clinical Medicine</i> , 2023, 12, 1214.	1.0	1
624	Established and Emerging Cancer Therapies and Cardiovascular System: Focus on Hypertension—Mechanisms and Mitigation. <i>Hypertension</i> , 2023, 80, 685-710.	1.3	7
625	Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
626	FDG PET/CT Prognostic Markers in Patients with Advanced Melanoma Treated with Ipilimumab and Nivolumab. <i>Radiology</i> , 2023, 307, .	3.6	6
627	Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutant. <i>International Journal of Clinical Oncology</i> , 2023, 28, 654-663.	1.0	1
628	Ocular adverse events associated with BRAF and MEK inhibitor combination therapy: a pharmacovigilance disproportionality analysis of the FDA adverse event reporting system. <i>Expert Opinion on Drug Safety</i> , 2023, 22, 175-181.	1.0	3
629	Hepatotoxicity of Small Molecule Protein Kinase Inhibitors for Cancer. <i>Cancers</i> , 2023, 15, 1766.	1.7	6
630	Novel therapeutics in low-grade serous ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2023, 33, 377-384.	1.2	4
631	Improved outcomes in women with BRAF-mutant melanoma treated with BRAF/MEK-targeted therapy across randomized clinical trials. A systematic review and meta-analysis. <i>Seminars in Oncology</i> , 2023, 50, 34-39.	0.8	2
632	ORC6, a novel prognostic biomarker, correlates with T regulatory cell infiltration in prostate adenocarcinoma: a pan-cancer analysis. <i>BMC Cancer</i> , 2023, 23, .	1.1	4
634	<i>In-silico</i> Molecular Docking and ADMET predictions of Pyrido[2,3-d]pyrimidine-2,4(1H,3H)-Dione Analogues as promising Antimicrobial, Antioxidant and Anticancer agents. <i>Polycyclic Aromatic Compounds</i> , 0, , 1-18.	1.4	2
636	Target Hyperactive ERK Signaling for Cancer Therapy. , 2023, , 1-39.		0
637	Effect of Food and a Proton-Pump Inhibitor on the Absorption of Encorafenib: An <i>In Vivo</i> — <i>In Vitro</i> — <i>In Silico</i> Approach. <i>Molecular Pharmaceutics</i> , 0, , .	2.3	6
638	BRAF-mediated brain tumors in adults and children: A review and the Australian and New Zealand experience. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
639	Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications. <i>Clinical Cancer Research</i> , 2023, 29, 2753-2760.	3.2	19

#	ARTICLE	IF	CITATIONS
640	Selected Approaches to Disrupting Protein-Protein Interactions within the MAPK/RAS Pathway. International Journal of Molecular Sciences, 2023, 24, 7373.	1.8	2
641	Clinical and molecular overview of immunotherapeutic approaches for malignant skin melanoma: Past, present and future. Critical Reviews in Oncology/Hematology, 2023, 186, 103988.	2.0	2
643	Targeted therapy. , 2023, , 205-411.		0
669	Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance. Frontiers in Endocrinology, 0, 14, .	1.5	7
672	Diagnosis and Management of Dermatologic Adverse Events from Systemic Melanoma Therapies. American Journal of Clinical Dermatology, 0, , .	3.3	0
697	Targeted Treatments for Cutaneous Melanoma. , 2023, , 1787-1800.		0
710	BRAF-Mutated Glioma. , 2023, , 51-66.		0
715	Targeting KRAS-Mutated Gastrointestinal Malignancies with Small-Molecule Inhibitors: A New Generation of Breakthrough Therapies. Drugs, 0, , .	4.9	0
726	BRAF is a tumour-agnostic drug target with lineage-specific dependencies. Nature Reviews Clinical Oncology, 2024, 21, 224-247.	12.5	1
748	Case report: A case of metastatic BRAFV600-mutated melanoma with heart failure treated with immune checkpoint inhibitors and BRAF/MEK inhibitors. Frontiers in Oncology, 0, 14, .	1.3	0